Cases & Deals

Baxter Ventures invests in Opsonix

Client(s) Baxter International Inc.

Jones Day represented Baxter Ventures in connection with its purchase of Series A Convertible Preferred Stock in a private placement by Opsonix, Inc., an immunotherapy company focused on developing and commercializing a pathogen-extracting therapy designed to remove infectious pathogens and toxins from circulating blood.